Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Dec;6(Suppl 2):S105.
doi: 10.21037/atm.2018.11.43.

Editorial on "Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer"

Spencer Hart  1 , Gopal Gupta  1
Affiliations
Editorial

Editorial on "Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer"

Spencer Hart et al. Ann Transl Med. 2018 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Comment on

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30. 10.3322/caac.21442 - DOI - PubMed
    1. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunititnib in metastatic renal-cell carcinoma. NEJM 2013;369:722-31. 10.1056/NEJMoa1303989 - DOI - PubMed
    1. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. NEJM 2018;378:1277-90. 10.1056/NEJMoa1712126 - DOI - PMC - PubMed
    1. Shelar S, Shim EH, Brinkley GJ, et al. Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer. Clin Cancer Res 2018;24:6433-46. 10.1158/1078-0432.CCR-18-1727 - DOI - PMC - PubMed